XOMA Corporation - Investor Relations

INVESTOR TOOLS

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

What is this?

Investor Relations

XOMA Corporation (Nasdaq: XOMA) combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government and has licensed certain of its fundamental technologies to more than 60 companies.

In 2010, XOMA partnered with Les Laboratoires Servier (Servier), France's leading independent pharmaceutical company, for the development of XOMA’s lead product gevokizumab (IL-1 beta modulating antibody). This collaboration brings together Servier's resources and expertise in pharmaceutical product development and commercialization with XOMA's expertise in biologics clinical development and manufacturing capabilities.

Today, XOMA's principal activities are centered on the advancement of gevokizumab, its preclinical pipeline and its biodefense business.

Gevokizumab (XOMA 052), a fully humanized allosteric monoclonal antibody that to interleukin-1β (IL-1β). XOMA is enrolling patients in two global Phase 3 non-infectious uveitis (NIU) clinical trials in both active NIU disease (EYEGUARD™ - A) and controlled NIU (EYEGUARD – C). The company is also conducting two Phase 2 proof-of-concept (POC) studies for moderate to severe inflammatory acne and erosive osteoarthritis of the hand. In addition, XOMA’s partner Servier is enrolling patients in a global Phase 3 clinical trial evaluating gevokizumab in patients with Behcet’s uveitis (EYEGUARD – B) and a POC study in patients with a history of acute coronary syndrome.
Preclinical pipeline includes the XMet program, which consists of three separate classes of Selective Insulin Receptor Modulators (SIRMs) antibodies: XMet A, XMet S and XMet D. XOMA is developing these antibodies to modulate the insulin receptor in a variety of ways for the potential treatment of diabetes and other metabolic syndromes.
Perindopril/Amlodipine Fixed-dose Combination (XOMA-985), an angiotensin converting enzyme (ACE) inhibitor perindopril (marketed under the trade name of ACEON^®), and a portfolio of three fixed-dose combination (FDC) product candidates where perindopril is combined with other active ingredient(s). The first FDC product candidate XOMA has elected to develop, perindopril arginine and amlodipine besylate, met its primary endpoint in a Phase 3 hypertension trial. The proprietary form of perindopril in each of the combination product candidates provides patent protection until 2023.
XOMA 3AB, an antibody candidate in preclinical development to neutralize the botulinum toxin, among the most deadly bioterrorism threats, under development through funding provided by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

XOMA's antibody technology platforms include an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, Bacterial Cell Expression (BCE), affinity maturation and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. Overall, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are currently in clinical development. XOMA is entitled to development-related milestones and royalties on antibodies covered under these licenses.